Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Teladoc Health heads into its October 30 quarterly results carrying 15.8% of its free float in short positions, a stock trading below $6, and a CEO who sold shares just weeks after a 30% post-earnings collapse.
Short interest is the central tension here. At 15.8% of free float, the position is elevated and has climbed sharply over the past month, up roughly 19% in absolute share terms since early September. The surge appears to date from the late-September period, when reported shares jumped from around 22.6 million to above 27 million in a matter of days. That said, the last week has seen a modest pullback, with short shares easing about 0.5% from the prior week's level. The borrow market tells a calmer story: cost to borrow is near 0.48%, low by any standard, and availability is running at 355%, meaning the pool of shares available to lend is more than three times the current short position. There is no squeeze pressure here. The ORTEX short score has also eased slightly from a recent peak above 67 to 64.7, suggesting the most intense phase of short rebuilding may have plateaued for now.
Options positioning offers no real counter-signal. The put/call ratio at 0.44 is almost exactly in line with its 20-day average of 0.445, and the z-score is effectively flat. The 52-week PCR range runs from 0.28 to 1.03, so current readings sit near the call-heavy end, implying that options traders are not particularly defensive heading into the print. The divergence between elevated short interest and a call-skewed options market is the clearest tension in the positioning picture: shorts are holding, but options desks are not hedging alongside them.
The Street offers little conviction for either camp. The analyst consensus has moved in one direction only since the July results: lower. After the stock collapsed 30% in a single session following Q2 earnings, Citigroup cut its target to $7.50 from $11.00 while maintaining a Neutral rating, and Evercore ISI trimmed to $7.50 from $10.00 at the same neutral stance. Canaccord Genuity, the lone Buy on the list, also pulled its target down to $10.00. The mean analyst target now stands at $7.59, roughly 31% above the current price of $5.77, but the targets have been moving toward the stock, not the stock toward the targets. Bulls point to Teladoc's whole-person virtual care platform as a differentiated long-term asset. Bears focus on expected membership declines, ACA subsidy roll-offs hurting the BetterHelp segment, and the company's lack of near-term pricing power. The valuation gives little clarity either way: EV/EBITDA at 4.6x looks undemanding, but the stock trades at a 0.71x price-to-book ratio and carries a deeply negative PE, and the factor score for short-score rank sits at the 7th percentile of its universe, meaning the model reads this as a structurally shorted name.
Insider activity adds a layer of concern that is hard to dismiss. The company's CEO, Charles DiVita, sold 18,327 shares on September 2 at $6.30, a discretionary sale with no 10b5-1 plan attached. He followed that with a further 17,805-share sale on September 11 at $6.10, again outside any pre-arranged plan. Combined, those two open-market sales totalled around $224,000 in proceeds. The Chief Legal Officer and President of International both sold on the same September 2 date. Taken together, TDOC insiders ran a net 90-day position of minus 75,942 shares, worth approximately $485,000. These are not giant sums relative to compensation, but the absence of 10b5-1 cover on the CEO sales, coming while the stock was still above $6 and just weeks after a catastrophic earnings miss, is not an encouraging signal.
The earnings history underscores the stakes. The July 2026 print produced a one-day move of minus 30%. The prior comparable event in the dataset showed a 3% bounce. Reaction after the print has tended to persist: the five-day move following the July collapse was minus 26%. With the next result due October 30, just 23 days away, the question that will dominate between now and then is whether the deceleration in revenue and the membership attrition that drove July's selloff have stabilised, or are still running.
See the live data behind this article on ORTEX.
Open TDOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
